Wed, Sep 17, 2014, 1:20 PM EDT - U.S. Markets close in 2 hrs 40 mins


% | $
Quotes you view appear here for quick access.

Concert Pharmaceuticals, Inc. Message Board

  • beepeeess beepeeess Feb 16, 2014 2:13 AM Flag

    2008 Fierce 15


    Concert Pharmaceuticals - 2008 Fierce 15

    The Scoop: Armed with a simple understanding that strategically replacing hydrogen molecules in therapeutics with deuterium can improve a drug's performance, Roger Tung created Concert Pharmaceuticals and raised $95.5 million in venture funds in less than two years, making believers of some of the most successful start-up artists in biotechnology. Now it's time to deliver the data.

    What makes it Fierce: Roger Tung isn't the only scientist to explore the potential for deuterium. But he's shown just how much an individual with keen scientific insight--along with a few good contacts in the venture field--can accomplish. He has swiftly banked enough money to get to the proof-of-concept stage, developed a platform approach to drug development that can spawn new clinical candidates as well as partnerships, and pushed hard to get it all up and running in a short period of time.

    In many ways Tung represents the potential biotechnology has to swiftly breed new companies and advance fresh ideas. He's taken an approach that allows the company to develop a portfolio of drug candidates, rather than put all of its eggs in one basket. And he's recruited more than 40 staffers to make it a reality.

    Concert's lead therapy is a deuterium-enhanced drug for hot flashes, a potential blockbuster in a field that has been roiled by safety issues now surrounding hormone replacement therapy. Phase I data from an initial trial should be in by the end of this year with Phase Ib data on drug-drug interactions arriving around early 2009.

    What to look for: Concert Pharma got off to a fast start by focusing on simple alterations that can deliver significant upgrades in therapeutics. Now it can start to partner with other developers to advance a variety of programs as it stays focused on delivering data for its own clinical candidates.

    This topic is deleted.
14.295+1.195(+9.12%)1:19 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.